TY - JOUR AU - Rivero, Jaydira Del AU - Enewold, Lindsey AU - Thomas, Anish PY - 2016 TI - Metastatic lung cancer in the age of targeted therapy: improving long-term survival JF - Translational Lung Cancer Research; Vol 5, No 6 (December 29, 2016): Translational Lung Cancer Research (Emerging Treatment Options for Brain Metastases from Non-small Cell Lung Cancer) Y2 - 2016 KW - N2 - Epidermal growth factor receptor ( EGFR ) mutations are the most frequent targetable genetic abnormality observed in non-small cell lung cancer (NSCLC). More than a decade after EGFR mutations were shown to predict sensitivity to EGFR-tyrosine kinase inhibitors (EGFR-TKI), retrospective cohort studies are now identifying and characterizing 5-year survivors. While these studies indicate subsets of patients achieving long-term survival, there is paucity of data pertaining to the long-term survival benefits of these targeted therapies at a population level. Improving access to molecular testing and treatment are key to maximizing the survival benefits at a population level. UR - https://tlcr.amegroups.org/article/view/11104